Autolus Therapeutics plc Files 8-K

Ticker: AUTL · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1730463

Autolus Therapeutics PLC 8-K Filing Summary
FieldDetail
CompanyAutolus Therapeutics PLC (AUTL)
Form Type8-K
Filed DateSep 26, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.000042
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, regulation-fd

Related Tickers: AUTL

TL;DR

AUTL filed an 8-K on 9/26/24 for Reg FD and financials.

AI Summary

Autolus Therapeutics plc filed an 8-K on September 26, 2024, reporting on events that occurred on the same date. The filing pertains to Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself are detailed in the provided text.

Why It Matters

This 8-K filing indicates Autolus Therapeutics plc is providing updates to the SEC regarding its financial statements and exhibits, and potentially other material information under Regulation FD.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain information that inherently poses a high risk.

Key Players & Entities

  • Autolus Therapeutics plc (company) — Registrant
  • September 26, 2024 (date) — Date of Report
  • Regulation FD Disclosure (event) — Item Information
  • Financial Statements and Exhibits (document_type) — Item Information

FAQ

What is the primary purpose of this 8-K filing by Autolus Therapeutics plc?

The 8-K filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on Regulation FD Disclosure and Financial Statements and Exhibits.

On what date was this 8-K filing reported?

The filing was reported as of September 26, 2024.

What is the company's principal executive office address?

The company's principal executive offices are located at The Mediaworks, 191 Wood Lane, London W12 7FP, United Kingdom.

What is the registrant's telephone number?

The registrant's telephone number is (44) 20 3829 6230.

What jurisdiction is Autolus Therapeutics plc incorporated in?

Autolus Therapeutics plc is incorporated in England and Wales.

Filing Stats: 673 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-09-26 07:00:14

Key Financial Figures

  • $0.000042 — nting one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Selec

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 26, 2024, Autolus Therapeutics plc (the "Company") will make a corporate update presentation at the KBC Life Sciences Conference. The slides from the presentation will also be used at one-on-one meetings with analysts and investors at the conference, and posted to the Company's website as an updated corporate presentation. The slides from the presentation are being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Exhibits

Item 9.01 Exhibits d) Exhibits Exhibit No. Description of Exhibit 99.1 Corporate Presentation dated September 26 , 2024 104 Cover Page Interactive Date File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTOLUS THERAPEUTICS PLC Dated: September 26, 2024 By: /s/Christian Itin, Ph.D. Name: Christian Itin, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.